Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
0.7200
-0.0300 (-4.00%)
Apr 21, 2025, 4:00 PM EDT - Market closed

Silexion Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Silexion Therapeutics stock has a target of 5.00, which predicts an increase of 594.44% from the current stock price of 0.72.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $5.00 $5.00 $5.00 $5.00
Change +594.44% +594.44% +594.44% +594.44%
* Price targets were last updated on Mar 20, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Silexion Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Feb '25Mar '25Apr '25
Strong Buy 111
Buy 000
Hold 000
Sell 000
Strong Sell 000
Total 111

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Maxim Group
Maxim Group
Strong Buy
Maintains
$9$5
Strong Buy Maintains $9$5 +594.44% Mar 20, 2025
Maxim Group
Maxim Group
Strong Buy
Initiates
$9
Strong Buy Initiates $9 +1,150.00% Nov 1, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-11.52
from -81.80
EPS Next Year
-0.98
from -11.52
Fiscal Year FY 2012 FY 2013 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2012 Dec 31, 2013 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
----
Revenue Growth
------
EPS
-65.74-81.80-11.52-0.98-1.34-1.72
EPS Growth
------
Forward PE
------
No. Analysts --3333
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 2024202520262027
High n/a n/a n/a
Avg n/a n/a n/a
Low n/a n/a n/a

Revenue Growth

Revenue Growth 2024202520262027
High - - -
Avg - - -
Low - - -

EPS Forecast

EPS 2024202520262027
High -11.85 -1.01 -1.38
Avg -11.52 -0.98 -1.34
Low -11.06 -0.94 -1.28

EPS Growth

EPS Growth 2024202520262027
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.